20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Financial News

Adrenergics completes venture financing

Adrenergics Inc., San Diego, Calif.   Business: Cardiovascular   Date completed: 2015-06-15   Type: Venture financing   Raised: $3 million   Investors: Avalon Ventures; GlaxoSmithKline plc   ...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Company News

Adrenergics, CadheRx Therapeutics, Calporta Therapeutics, GlaxoSmithKline cancer, cardiology, endocrine/metabolic news

Avalon Ventures and GlaxoSmithKline launched three build-to-buy companies, Adrenergics, CadheRx and Calporta, each with $3 million in series A funding and $7 million in R&D support. The companies will be housed at Avalon’s COI Pharmaceuticals...
07:00 , Jun 22, 2015 |  BioCentury  |  Finance

Build-to-buy basket

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Avalon Ventures doubled the number of build-to-buys in their deal to six, including the first build-to-buy that is homegrown by the VC. The newest cohort of companies includes Adrenergics Inc.,...
02:10 , Jun 16, 2015 |  BC Extra  |  Financial News

Avalon, GSK launch three more biotechs

Avalon Ventures and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) launched three build-to-buy companies, each with $3 million in series A funding and $7 million in R&D support. Adrenergics Inc. is focused on therapies for dilated cardiomyopathy. CadheRx...